¿Dónde comprar?

Dr. Horacio Astudillo

Socio fundador, Presidente del Consejo y Director Científico de Nanopharmacia Group

Médico Cirujano y Partero, egresado de la Escuela Superior de Medicina del Instituto Politécnico Nacional (IPN) de México.

Maestro en Ciencias en la especialidad en Genética y Biología Molecular del Centro de Investigación y Estudios Avanzados del IPN (CINVESTAV-IPN).

Doctor en Ciencias en la especialidad en Biomedicina Molecular (ENMyH-IPN).

Investigador del Laboratorio de Investigación Traslacional y Terapia Celular del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS).

Actividad Profesional

  • Socio fundador, Presidente del Consejo y Director Científico de Nanopharmacia Group
  • Miembro del Sistema Nacional de Investigadores (Nivel I).
  • Profesor Titular de la Escuela de Graduados en Sanidad de la Escuela Medico Militar de la Universidad del Ejército y las Fuerzas Armadas de México (2000-2013).
  • Investigador Visitante del Centro de Investigación del Cáncer Alemán en la Ciudad de Heidelberg, Alemania (2002, 2003 y 2004) y en el MD Anderson Cancer Center de la Universidad de Texas en la Ciudad de Houston Texas, USA (2005).
  • Líder de opinión y asesor científico para proyectos, programas, nuevas moléculas ó nuevos sistemas de detección basados en biomarcadores moleculares para medicina personalizada en cáncer para múltiples compañías farmacéuticas y de diagnóstico molecular nacionales e internacionales.
  • Actualmente responsable de 5 programas nacionales para la personalización de nuevas drogas en el Cáncer a nivel nacional (KRAS: MERCK, AMGEN, PiSA; EGFR: ASTRA-ZENECA; ALK: PFIZER).
  • Co-Editor de la Revista Mexicana de Mastología desde 2012.
  • Miembro del Comité Editorial del Journal of Cancerology Desde 2015.
  • Miembro de las siguientes sociedades y comités científicos:
    • Miembro Activo, de la New York Academy of Sciences, desde 1996.
    • Consultor y Evaluador, del Consejo Nacional de Ciencia y Tecnología (CONACYT), desde 1998
    • Miembro Activo, de la Sociedad Nacional de Genética Humana de México desde 2004.
    • Active Allied-member, de la American Society of Clinical Oncology (ASCO) desde 2004.
    • Associate member, de la European Society for Medical Oncology (ESMO) desde 2005.
    • Miembro Activo, de la Sociedad Nacional de Inmunología (México) desde 2005.
    • Active member de la European Association for Cancer Research (EACR) desde 2005.
    • Miembro Activo de la Sociedad Latinoamericana y el Caribe de la Oncología Médica (SLACOM) desde 2006.
    • Miembro Activo de la Asociación Mexicana de Mastología (Comisión en Genética) desde 2006.
    • Active member de la American Association for Advancing of Science (AAAS) desde 2006.
    • Active member de la American Association for Cancer Research (AACR) desde 2008.
    • Miembro Activo Aliado de la Sociedad Mexicana de estudios Oncológicos (SMeO) desde 2010.
    • Miembro del Comité Editorial de la Revista Mexicana de Mastología desde 2010.
    • Miembro del Comité Editorial de la Gaceta Mexic0ana de Oncología desde 2010.

premios

  • Premio Latinoamericano en Investigación Oncológica “Fundación Aida Weiss” 1999, en la categoría cátedra, programa o plan de estudios en oncología.
  • Premio al mejor trabajo presentado en el congreso de la CELL DEATH SOCIETY 1999 en el Queen College of Medicine, Nueva York, USA.
  • Ganador del Best Poster Award 2004 en el Congreso de la Sociedad Europea en Oncología Médica (ESMO) realizado en la ciudad de Viena, Austria.
  • Premio al mejor protocolo de investigación científica (2º Lugar) del programa PROGRESA de la farmacéutica Ely-Lilly de México.
  • Premio Nacional de Investigación 2006 (1er Lugar) “Dr. Héctor Márquez Monter”de la Sociedad Mexicana de Genética Humana A.C. y la Universidad de Chihuahua durante el XXXI Congreso Nacional de Genética Humana “La Genética Médica y su Evolución”
  • Premio Nacional de Investigación en Oncología 2014 de la Sociedad Mexicana de estudios Oncológicos (SMeO).
  • Premio Nacional en Ciencia y Tecnología de Alimentos 2016 con el trabajo “Resveratrol y Cáncer de Mama” de CONCACyT y Fundación Coca-Cola, en su 40º edición.

publicaciones

  • Zinc associated nanomaterials and their intervention in emerging respiratory viruses: Journey to the field of biomedicine and biomaterials. CG Rodelo, RA Salinas, EA JaimeArmenta, S Armenta, et al. (2022) Coordination Chemistry Reviews 457, 214402.
  • Bio-Acceptable 0D and 1D ZnO nanostructures for cancer diagnostics and treatment. B Ortiz-Casas, A Galdámez-Martínez, J Gutiérrez-Flores, AB Ibañez, et al. (2021) Materials Today 50, 533-569.
  • Development of an alternative saliva test for diagnosis of SARS-CoV-2 using TRIzol: Adapting to countries with lower incomes looking for a large-scale detection program. H Miranda-Ortiz, EA Fernández-Figueroa, EB Ruíz-García, et al. (2021) Plos One 16 (8), e0255807.
  • HOX transcript antisense RNA HOTAIR abrogates vasculogenic mimicry by targeting the AngiomiR-204/FAK axis in triple negative breast cancer cells. A Lozano-Romero, H Astudillo-de la Vega, MCR Terrones-Gurrola, et al. (2020) Non-coding RNA 6 (2), 19.
  • Osteopontin expression and its relationship with prognostic factors in diffuse large B- cell lymphoma. G Barranco, E Fernández, S Rivas, R Quezada, D Nava, J Aguilar, et al. (2019) Hematology Reports 11 (3).
  • Efecto de la suplementación con ácidos grasos omega-3 sobre la toxicidad secundaria a quimioterapia neoadyuvante en pacientes con cáncer de mama localmente avanzado: ensayo …F Rosa Oliva, A Meneses García, H Ruiz Calzada, H Astudillo de la Vega, et al. (2019) Nutrición Hospitalaria 36 (4), 769-776.
  • MicroRNA-143 is associated with pathological complete response and regulates multiple signaling proteins in breast cancer. R García-Vázquez, LA Marchat, E Ruíz-García, H Astudillo-De la Vega, et al. (2019) Technology in Cancer Research & Treatment 18, 1533033819827309.
  • Guía de Práctica Clínica Nacional para el manejo del cáncer de pulmón de células no pequeñas en estadios tempranos, localmente avanzados y metastásicos. F Barrón-Barrón, E Guzmán-De Alba, J Alatorre-Alexander, et al. (2019) Salud Pública de Mexico 61 (3, may-jun), 359-414.
  • Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the … H Astudillo de la Vega US Patent 10,285,963 (2019)
  • HypoxamiRs profiling identify miR-765 as a regulator of the early stages of vasculogenic mimicry in SKOV3 ovarian cancer cells. YM Salinas-Vera, D Gallardo-Rincón, R García-Vázquez, et al. (2019) Frontiers in Oncology 9, 381.
  • National Clinical Practice Guidelines for the management of non-small cell lung cancer in early, locally advanced and metastatic stages. Extended version. F Barrón-Barrón, E Guzmán-De Alba, J Alatorre-Alexander, et al. (2019) Salud Publica de Mexico 61 (3), 359-414.
  • DNA repair proteins as therapeutic targets in ovarian cancer. C López-Camarillo, DG Rincón, E Ruiz-García, H Astudillo-de la Vega, et al. (2019) Current Protein and Peptide Science 20 (4), 316-323.
  • A novel OsteomiRs expression signature for osteoblast differentiation of human amniotic membrane-derived mesenchymal stem cells. M Avendaño-Félix, L Fuentes-Mera, R Ramos-Payan, M Aguilar-Medina, et al. (2019) BioMed Research International.
  • Dietary compounds as epigenetic modulating agents in cancer. Á Carlos-Reyes, JS López-González, M Meneses-Flores, et al. (2019) Frontiers in Genetics 10, 79.
  • Epirubicina neoadyuvante con o sin docetaxel secuencial en el tratamiento del cáncer de mama avanzado: evaluación de la respuesta patológica completa y tolerabilidad de la … N Ramírez-Torres, A Pérez-Puentes, C Moctezuma-Meza, et al. (2019) Cirugia y Cirujanos 87 (1), 59-68.
  • Clinical and functional analysis of SOX9 in colorectal cancer. E Lizarraga, E Ruiz Garcia, C Lopez-Camarillo, A Meneses, H Astudillo, et al. (2019) Journal of Clinical Oncology 37 (4_suppl), 519-519.
  • AngiomiRs: MicroRNAs driving angiogenesis in cancer. YM Salinas-Vera, LA Marchat, D Gallardo-Rincón, E Ruiz-García, et al. (2019) International Journal of Molecular Medicine 43 (2), 657-670.
  • MicroRNAs driving angiogenesis in cancer (Review). YM Salinas-Vera, LA Marchat, D Gallardo-Rincon, E Ruiz-Garcia, et al. (2019) J. Mol. Med. 43, 657-670.
  • Oncobiome at the forefront of a novel molecular mechanism to understand the microbiome and cancer. H Astudillo-de la Vega, O Alonso-Luna, J Ali-Pérez, C López-Camarillo, et al. Translational Research and Onco-Omics Applications in the Era of Cancer … Springer Books (2019).
  • Effects of omega-3 fatty acids supplementation on neoadjuvant chemotherapy-induced toxicity in patients with locally advanced breast cancer: a randomized, controlled, double … F De la Rosa Oliva, AM García, HR Calzada, H Astudillo-de la Vega, et al. (2019) Nutrición Hospitalaria: Organo Oficial de la Sociedad española de nutrición …
  • Molecular epidemiology of ALK rearrangements in advanced lung adenocarcinoma in Latin America. O Arrieta, AF Cardona, G Bramuglia, G Cruz-Rico, L Corrales, C Martín, et al. (2019) Oncology 96 (4), 207-216.
  • Association between SOX9 expression in Mexican patients with early colon cancer stage. E Ruiz-Garcia, T Galicia, EF Figueroa, S Lino-Silva, C Lopez-Camarillo, et al. (2018) Cancer Research 78 (13 Supplement), 4221-4221.
  • Antiproliferative effect of cannabinoid receptor agonists on rectal cancer lines. AO Gómez, P Luna-Merlos, VMG Hernández, AM García, et al. (2018) Cancer Research 78 (13 Supplement), 1903-1903.
  • let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer. R García-Vázquez, D Gallardo Rincón, E Ruiz-García, A Meneses García, et al. (2018) Oncology Reports 39 (6), 3086-3094.
  • Gastric cancer in Latin America. E Ruíz-García, J Guadarrama-Orozco, S Vidal-Millán, LS Lino-Silva, et al. (2018) Scandinavian Journal of Gastroenterology 53 (2), 124-129.
  • Guía de Práctica Clínica Nacional para el tratamiento del cáncer de pulmón de células no pequeñas en estadios tempranos, localmente avanzados y metastásicos. F Barrón Barrón, E Guzmán de Alba, J Alatorre Alexander, et al. (2018) Gaceta Mexicana de Oncología 17 (4), 201-232.
  • Predictive value of LRP8, KPNA2 and GDF15 expression to anthracycline/taxane based chemotherapy response in patients with locally advanced breast cancer H Maldonado-Mtz, AL Oscar, A Flores-Perez, MG Abelardo, et al. (2017) Cancer Research 77 (13 Supplement), 1786-1786.
  • Frequency and prognostic value of PI3KCA mutations in early stage of colorectal cancer in Mexican patients. E Ruiz-Garcia, A Ortega, A Bahena, E Fernandez, G Calderillo, et al. (2017) Cancer Research 77 (13 Supplement), 2728-2728.
  • Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma. E Ruiz-Garcia, JA Matus-Santos, JA Guadarrama-Orozco, et al. (2017) Journal of Global Oncology 4, 1-5.
  • MicroRNAs driving invasion and metastasis in ovarian cancer: Opportunities for translational medicine. C Palma Flores, R García-Vázquez, D Gallardo Rincón, E Ruiz-García, et al. (2017) International Journal of Oncology 50 (5), 1461-1476.
  • A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. R García-Vazquez, E Ruiz-García, A Meneses Garcia, et al. (2017) Tumor Biology 39 (6), 1010428317702899.
  • ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site. R Grajales-Álvarez, A Martin-Aguilar, JA Silva, JG de la Garza-Salazar, et al. (2017) Molecular and Clinical Oncology 6 (5), 643-650.
  • Search of the p. M918T mutation in the RET oncogene in Mexican adult patients with medullary thyroid carcinoma. E Ruiz-Garcia, S Vidal-Millan, A Lopez-Yañez, JAP Torres, et al. (2017) Experimental and Clinical Endocrinology & Diabetes 125 (04), 218-222.
  • Abstract P2-11-10: Effect of supplementation with eicosapentaenoic and docosahexaenoic omega-3 polyunsaturated fatty acid on the chemotoxicity in Mexican patients with locally … F DelaRosa-Oliva, E Ruiz-Garcia, E Gomez, C Arce-Salinas, et al. (2017) Cancer Research 77 (4 Supplement), P2-11-10-P2-11-10.
  • Malignant Transforming Mechanisms of Human Papillomavirus H Astudillo-de la Vega, E Ruiz-Garcia, C Lopez-Camarillo, et al. (2017) Cervical Cancer, Springer Books 35-56.
  • Suppression of cell migration is promoted by miR-944 through targeting of SIAH1 and PTP4A1 in breast cancer cells. A Flores-Pérez, LA Marchat, S Rodríguez-Cuevas, VP Bautista, et al. (2016) BMC Cancer 16 (1), 1-12.
  • Dual targeting of ANGPT1 and TGFBR2 genes by miR-204 controls angiogenesis in breast cancer. A Flores-Pérez, LA Marchat, S Rodríguez-Cuevas, V Bautista-Piña, et al. (2016) Scientific Reports 6 (1), 1-18.
  • Reduction in hepatocyte growth factor serum levels is associated with improved prognosis in advanced lung adenocarcinoma patients treated with afatinib: a phase II trial. O Arrieta, G Cruz-Rico, E Soto-Perez-de-Celis, LA Ramírez-Tirado, et al. (2016) Targeted Oncology 11 (5), 619-629.
  • Braf V600E mutation in melanoma: translational current scenario. JA Guadarrama-Orozco, A Ortega-Gómez, EB Ruíz-García, et al. (2016) Clinical and Translational Oncology 18 (9), 863-871.
  • Next generation sequencing (NGS) of dihydropyrimidine dehydrogenase (DPYD) gene in Mexican patients with gastrointestinal (GI) carcinomas. E Ruiz-Garcia, A Lopez-Yanez, A Ortega, J Guadarrama-Orozco, et al. (2016) Cancer Research 76 (14 Supplement), 3173-3173.
  • Methylation landscape of human breast cancer cells in response to dietary compound resveratrol. R Medina-Aguilar, C Pérez-Plasencia, LA Marchat, P Gariglio, et al. (2016) PLoS One 11 (6), e0157866.
  • Effect of adding sequential docetaxel to neoadjuvant epirubicin in treatment of advanced breast cancer: Preliminary results of tumor response. N Ramirez-Torres, J Asbun-Bojalil, C Moctezuma, A Perez Puente, et al. (2016) Journal of Clinical Oncology 34 (15_suppl), e12509-e12509.
  • Prognostic impact of complete pathological response and lymph node status in patients with advanced breast cancer treated with high-dose neoadjuvant epirubicin. N Ramirez-Torres, A Perez-Puentes, R Rivas-Ruiz, JO Talavera, et al. (2016) Gaceta Mexicana de Oncologia 15 (3), 128-137.
  • Impacto pronóstico de la respuesta patológica completa y del estado ganglionar en pacientes con cáncer de mama avanzado tratadas con dosis alta de epirrubicina neoadyuvante. N Ramírez-Torres, A Pérez-Puentes, R Rivas-Ruiz, JO Talavera, et al. (2016) Gaceta Mexicana de Oncología 15 (3), 128-137.
  • Differential proteomic analysis reveals that EGCG inhibits HDGF and activates apoptosis to increase the sensitivity of non‐small cells lung cancer to chemotherapy. A Flores‐Pérez, LA Marchat, LL Sánchez, D Romero‐Zamora, et al. (2016) PROTEOMICS–Clinical Applications 10 (2), 172-182.
  • Micro-RNAs as positive biomarkers of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal carcinoma. EB Ruiz Garcia, G Lopez-Rosas, C Lopez-Camarillo, S Namendys-Silva, et al. (2016) Journal of Clinical Oncology 34 (4_suppl), 624-624.
  • ALK rearrangements epidemiology in Latin America (CLICaP). O Arrieta Rodriguez, AF Cardona, G Bramuglia, G Cruz-Rico, C Martin, et al. (2015) JOURNAL OF THORACIC ONCOLOGY 10 (9), S696-S697.
  • Plasma HGF Reduction Is Associated with Better Prognosis in EGFR-Positive Advanced Lung Adenocarcinoma Patients Treated with Afatinib. O Arrieta Rodriguez, G Cruz-Rico, LA Ramirez-Tirado, J Negueb, et al. (2015) JOURNAL OF THORACIC ONCOLOGY 10 (9), S320-S321.
  • Determination of the receptor for advanced glycation end-products in breast cancer patients previous chemotherapy. JA Guadarrama-Orozco, EB Ruiz-García, HA Maldonado-Martinez, et al. (2015) Cancer Research 75 (15 Supplement), 5292-5292.
  • A pilot study of nimotuzumab plus single agent chemotherapy as second-or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. L Cetina, T Crombet, R Jiménez-Lima, S Zapata, M Ramos, S Avila, et al. (2015) Cancer Biology & Therapy 16 (5), 684-689.
  • The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. O Arrieta, AF Cardona, L Corrales, AD Campos-Parra, R Sánchez-Reyes, et al. (2015) Lung cancer 87 (2), 169-175.
  • Determination of dihydropyrimidine dehydrogenase (DPYD) gene single-nucleotide polymorphism (SNP) in Mexican patients with locally advanced esophageal carcinoma. E Ruiz-Garcia, A Lopez-Yañez, G Caderillo-Ruiz, CZ Deneken, C Diaz, et al. (2015) Journal of Clinical Oncology 33 (3_suppl), 93-93.
  • Analysis of the efficacy of neoadjuvant treatment on adding preoperative sequential fluorouracil, epirubicin and cyclophosphamide in patients with advanced breast cancer … N Ramírez-Torres, C Moctezuma-Meza, J Asbun-Bojalil, et al. (2015) Gaceta Mexicana de Oncologia, 3-12.
  • Análisis de la efectividad del tratamiento neoadyuvante al añadir docetaxel secuencial a fluorouracilo, epirrubicina y ciclofosfamida en pacientes con cáncer de mama avanzado … N Ramírez-Torres, C Moctezuma-Meza, J Asbun-Bojalil, et al. (2015) Gaceta Mexicana de Oncología 14 (1), 3-12.
  • Nonbilayer phospholipid arrangements are Toll-like receptor-2/6 and TLR-4 agonists and trigger inflammation in a mouse model resembling human lupus. C Wong-Baeza, A Tescucano, H Astudillo, A Reséndiz, C Landa, et al. (2015) Journal of Immunology Research.
  • Proteomic analysis identifies endoribouclease EhL-PSP and EhRRP41 exosome protein as novel interactors of EhCAF1 deadenylase. I López-Rosas, LA Marchat, BG Olvera, N Guillen, C Weber, et al. (2014) Journal of Proteomics 111, 59-73.
  • Comparative proteomic profiling of triple-negative breast cancer reveals that up- regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9. MAM Lino, Y Palacios-Rodríguez, S Rodríguez-Cuevas, V Bautista-Piña, et al. (2014) Journal of Proteomics 111, 198-211.
  • Proteomic profiling reveals that EhPC4 transcription factor induces cell migration through up-regulation of the 16-kDa actin-binding protein EhABP16 in Entamoeba histolytica. OH de la Cruz, M Muñiz-Lino, N Guillén, C Weber, LA Marchat, et al. (2014) Journal of Proteomics 111, 46-58.
  • Los microRNA: nuevos biomarcadores en cáncer de mama. C López-Camarillo, MA Fonseca-Sánchez, H Astudillo-de la Vega, et al. (2014) Rev Mex Mastol 4 (3), 100-107.
  • Análisis de la efectividad de epirrubicina neoadyuvante de alta dosis al usar 4 vs. 6 ciclos en pacientes con cáncer de mama localmente avanzado. N Ramírez-Torres, A Pérez-Puentes, H Astudillo-de la Vega. (2014) Rev Mex Mastol 4 (3), 91-99.
  • MicroRNAs: novel biomarkers in breast cancer. C López-Camarillo, MA Fonseca-Sánchez, H Astudillo-de la Vega, et al. (2014) Revista Mexicana de Mastología 4 (3), 100-107.
  • Análisis de efectividad de la epirrubicina neoadyuvante en dosis convencional en pacientes con cáncer de mama localmente avanzado. E Ruiz-García, N Ramírez-Torres, C López-Camarillo, LA Marchat, et al. (2014) Revista Mexicana de Mastología 4 (3), 81-86.
  • Serum Albumin (SA) as a Predictor of Response to Chemotherapy in Patients with Locally Advanced (LA) Esophageal Cancer. RG Erika, RS Daniel, C German, ÑS Sylvio, ZM Jesus, D Consuelo, et al. (2014) Annals of Oncology 25, ii53.
  • Metastasic colorrectal cancer, towards a customized treatment. FJ Ochoa-Carrillo, A Ruiz-Garcia, H Astudillo-de la Vega, et al. (2014) Gaceta Mexicana de Oncologia 13 (1), 39-46.
  • Cáncer colorrectal metastásico, hacia un tratamiento personalizado. FJ Ochoa-Carrillo, VH de la Astudillo, I Alvarado-Cabrero, E Ruiz-García, et al. (2014) Gaceta Mexicana de Oncologia 13, 39-46.
  • Stem Cells in Pancreatic Cancer. JA Guadarrama-Orozco, E Ruiz-Garcia, JC Casarez-Price, et al. Stem Cells in Cancer: Should We Believe or Not?, Springer Books (2014) 167-189.
  • Biomarcadores del cáncer de mama vs firmas genómicas: hacia la búsqueda de una terapia personalizada. H Astudillo-de la Vega, É Ruiz-García, D Muñoz-González, et al. (2014) Revista Mexicana de Mastología 4 (1), 9-17.
  • Prevalence of BRAF V600E mutation in metastatic melanoma of Mexican Mestizo population. E Ruiz-Garcia, A Meneses, H Martinez-Said, JL Aguilar-Ponce, A Mohar, et al. (2013) EUROPEAN JOURNAL OF CANCER 49, S875-S875.
  • National consensus of diagnosis and treatment of non-small cell lung cancer. O Arrieta, E Guzman-de Alba, LF Alba-López, A Acosta-Espinoza, et al (2013) Revista de Investigacion Clinica; organo del Hospital de Enfermedades de la …
  • Síntesis de nanotransportadores poliméricos de nanopartículas de plata y su efecto sobre la remisión neoplásica: estudio in vitro e in vivo en modelo murino. R Casañas Pimentel, E San Mantín Martínez, G Pérez Ishiwara, et al. Instituto Politecnico Nacional (2013).
  • Guías de tratamiento médico del cáncer de pulmón de células no pequeñas en el ISSSTE (tercera y última parte). AAEV Solís, CAH Hernández, FA Sarvide, EF González, et al. (2013) Revista de Especialidades Médico-Quirúrgicas 18 (4), 328-330.
  • Guías de tratamiento médico del cáncer de pulmón de células no pequeñas en el ISSSTE (segunda parte). AAEV Solís, CAH Hernández, FA Sarvide, EF González, et al. (2013) Revista de Especialidades Médico-Quirúrgicas 18 (3), 241-247.
  • Guías de tratamiento médico del cáncer de pulmón de células no pequeñas en el ISSSTE. AAEV Solís, CAH Hernández, FA Sarvide, EF González, et al. (2013) Revista de Especialidades Médico-Quirúrgicas 18 (2), 138-141.
  • The Molecular Biology of Inflammatory Breast Cancer. H Astudillo-de la Vega, E Ruiz-Garcia, P Juarez-Sanchez, et al. (2013) Inflammatory Breast Cancer, Springer Books. 109-117.
  • Consenso nacional de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. O Arrieta, E Guzmán-de Alba, LF Alba-López, A Acosta-Espinoza, et al. (2013) Revista de Investigación Clínica 65 (S1), 5-84.
  • Male urethral pap smears and peniscopy examination and polymerase chain reaction human papillomavirus correlation.  M Lilia Tena‐Suck, A Alarcón‐Herrera, A Tirado‐Sánchez, F Rösl, et al. (2012) Diagnostic Cytopathology 40 (7), 597-603.
  • Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation … M Ramos-Suzarte, P Lorenzo-Luaces, NG Lazo, ML Perez, JL Soriano, et al. (2012) Cancer Biology & Therapy 13 (8), 600-605.
  • Toll-like receptor 7 and 9 (TLR 7 and TLR 9) expression in biopsies of in situ cervical cancer. MA Moreno-Eutimio, R Aragon-Franco, C Lopez-Macias, AJ Silva, et al. (2012) Journal of Clinical Oncology 30 (15_suppl), e15584-e15584.
  • Cost-effectiveness analysis of neoadjuvant chemotherapy with intensive dose of epirubicin and different cycles in patients with locally advanced breast cancer: 4 FE100C … N Ramirez, JE Herrera, JF Chavez, H Astudillo. (2012) Journal of Clinical Oncology 30 (15_suppl), e11565-e11565.
  • Proliferation and apoptosis genes as prognostic and predictive factors in breast cancer: Towards personalized medicine. H Maldonado-Martinez, MÁ Pluma-Jiménez, R Grajales-Álvarez, et al. (2011) Gaceta Mexicana de Oncologia, 210-221.
  • Genes de proliferación y apoptosis como factores predictivos y pronósticos en el cáncer de mama: hacia una medicina personalizada. H Maldonado-Martinez, MÁ Pluma-Jiménez, R Grajales-Álvarez, et al. (2011) GAMO 10 (4), 210.
  • High response rates with bevacizumab, docetaxel, and carboplatin in patients with HER2-negative advanced breast cancer: An experience of 22 case reports. G Tellez-Trevilla, P Cabrera-Galeana, E Gomez-Plata, JL Barrera-Franco, et al. (2011) Journal of Clinical Oncology 29 (15_suppl), e11538-e11538.
  • Molecular analysis of KRAS polymorphism mutation using a high-resolution melting system in a large mCRC patients sample in Mexico. H Astudillo, EB Ruiz-Garcia, VM Vazquez, J Bastarrachea, et al. (2011) Journal of Clinical Oncology 29 (15_suppl), e14132-e14132.
  • Proteomic analysis of TLR7 expression and clinical correlation in prostate carcinomas compared with prostatic benign lesions. R Aragon-Franco, H Rosas-Hernandez, G Garrido-Sanchez, H Astudillo. (2011) Journal of Clinical Oncology 29 (15_suppl), e15195-e15195.
  • 6032 POSTER Colonic Tumour Localization, Clinicopathological Patterns and Incidence of Colorectal Carcinoma in Mexican Population. E Ruiz-Garcia, H Astudillo-de la Vega, JL Aguilar-Ponce, et al. (2011) European Journal of Cancer, S400-S401.
  • 1101 POSTER Identification of KRas Mutational Polymorphism by Molecular Analysis Using High-resolution Melting System in a Large MCRC Mexican Sample. H Astudillo-de la Vega, P Romero-Garcia, JA Silva, R Villalobos-Valencia, et al. (2011) European Journal of Cancer, S124-S125.
  • 5063 POSTER Improvement of Neoadjuvant Therapy Response by Using 4FE100C Vs 6FE100C in Locally Advanced Breast Cancer. N Ramirez-Torres, A Perez-Puente, J Asbun-Bojalil, E Ruiz-Garcia, et al. (2011) European Journal of Cancer, S349.
  • 1150 POSTER Analysis of Biological Markers, Tumoral Predictors and Clinical Features as Prognosis Factors to Cnemotherapy Response in Metastatic Carcinomas of Unknown Primary Site. R Grajales-Alvarez, G Martinez-Martinez, AE Martin-Aguilar, JA Silva, et al. (2011) European Journal of Cancer, S138-S139.
  • Abstract P1-11-21: Effectiveness Analysis of Neoadjuvant Treatment by Using 4FE100C vs 6FE100C in Patients with Advanced Breast Cancer. N Ramirez-Torres, A Perez-Puentes, H Astudillo-de la Vega. (2010) Cancer Research 70 (24 Supplement), P1-11-21-P1-11-21.
  • A RETROSPECTIVE ANALYSIS OF GALLBLADDER CANCER PATIENTS REFERRED TO THE NATIONAL CANCER INSTITUTE IN MEXICO BETWEEN 2004- 2009. E Ruiz-Garcia, G Calderillo-Ruiz, H Astudillo-De la Vega, R Martinez, et al. (2010) ANNALS OF ONCOLOGY 21, 248-249.
  • E‐cadherin expression in male urethral smears and correlation with PCR‐based detection of human papillomavirus infection. ML Tena‐Suck, A Alarcón, F Rösl, HA la Vega. (2010) Diagnostic Cytopathology 38 (8), 583-589.
  • Association between penoscopy data and urethral cytology among men with partners who had cervical lesions associated with human papilloma virus. A Alarcon-Herrera, A Cervantes-Sánchez, T Meneses-Miranda, et al. (2010) Gaceta Medica de Mexico 146 (4), 274-280.
  • El papel de la quimiorresistencia en los tumores sólidos. H Astudillo-de la Vega, RG Erika, MC Jorge, OC Francisco. (2010) GAMO 9 (3), 117-126.
  • El papel de los Toll Like Receptors (TLRs) en la respuesta inmune innata contra el cáncer cérvico-uterino. F Aragón-Franco, C López-Macías, I Estrada-García, et al. (2010) Revista de Sanidad Militar [revista en internet], 287-288.
  • Penoscopia y citología uretral en hombres con parejas que presentan lesiones cervicales por virus del papiloma humano. A Alarcón-Herrera, A Cervantes-Sánchez, T Meneses-Miranda, et al. (2010) Gaceta Medica de Mexico 146 (4), 274-280.
  • Polymorphism detection of K-Ras mutations using high-resolution melting analysis in Mexican patients with metastatic colorectal cancer (mCRC). H Astudillo, J Sanchez-Guillen, P Romero-Garcia, J Bastarrachea-Ortiz, et al. (2009) Journal of Clinical Oncology 27 (15_suppl), e15135-e15135.
  • RAPD markers associated with quercetin accumulation in Psidium guajava. IA Feria-Romero, H Astudillo-De la Vega, MA Chavez-Soto, E Rivera-Arce, et al. (2009) Biologia Plantarum 53 (1), 125-128.
  • Biomarker analysis by tissue microarray technology of Bik, Bcl-2, Bax, ER-α, ER-β, Her2/neu, PCNA, P53, pRB proteins and apoptotic index (by TUNEL) in breast cancer Mexican … N Garcia-Hernandez, D Arenas, B Murillo-Ortiz, A Meneses, D Muñoz, et al. (2009) Cancer Research 69 (2 Supplement), 4043.
  • Association of the polymorphisms CYP19 (TTTA) n in treatment response to hormone therapy based in aromatase inhibitors in breast cancer patients. B Murillo-Ortiz, R Castillo-Valenzuela, S Martínez-Garza, A Moreno-Perez, et al. (2009) Cancer Research 69 (2 Supplement), 3033.
  • Biomarker analysis by tissue microarray technology of Bilk, Bcl-2, Bax, ER-alpha, ER- beta, Her2/neu, PCNA, P53, pRB proteins and apoptotic index (by TUNEL) in breast cancer … A Garcia-Hernandez, D Arenas, B Murillo-Ortiz, A Meneses, D Munoz, et al. (2009) Cancer Research 69 (2), 264S-265S.
  • Phosphatase and tensin homologue and pituitary tumor-transforming gene in pituitary adenomas. Clinical-pathologic and immunohistochemical analysis. ML Tena-Suck, A Ortiz-Plata, HA de la Vega. (2008) Annals of Diagnostic Pathology 12 (4), 275-282.
  • FUNCTIONALITY AND VIABILITY AFTER ENZYM DISAGGREGATION OF NEONATAL PIG ISLETS.: 1672. B Ramírez-González, MG López-Santos, LM Dorantes-Álvarez, et al. (2008) Transplantation 86 (2S), 554.
  • SURVIVAL OF NEONATAL PIG ISLETS IN DIFFERENT CULTURES: 1671. MG Lopez-Santos, B Ramírez-González, O Ramirez-Espinosa, et al. (2008) Transplantation 86 (2S), 554.
  • Proteomic analysis for NBK, Bcl-2, Bax genes and apoptosis (TUNEL) in breast cancer biopsies (stage II/III) by tissue microarray technology. N García-Hernández, D Arenas, F Salamanca, A Calderon-Garcidueñas, et al. (2008) Journal of Clinical Oncology 26 (15_suppl), 22194-22194.
  • PCNA as potential marker for cervix neoplastic and preneoplastic lesions. H Maldonado, C Perea-Montoya, S Cano, J De la Cruz, et al. (2008) Journal of Clinical Oncology 26 (15_suppl), 16581-16581.
  • A phase II trial of the use of 4, 4’-dihydroxybenzophenone-2, 4-dinitrophenyl- hydrazone (A-007) topical gel in the treatment of high-grade squamous intraepithelial lesions … D Munoz, D Cantu, A Gonzalez, A Meneses, A Mohar, et al. (2007) Journal of Clinical Oncology 25 (18_suppl), 5593-5593.
  • Expression of the receiver of the factor of tumorlike necrosis in monocytes infected by human cytomegalovirus LM Aguilar-Anguiano, JD Villalba-Magdaleno, FV Ortiz-Navarrete, et al. (2007) Revista de Sanidad Militar 61 (6), 341-348.
  • Telomerase activity, estrogen receptors (α, β), Bcl-2 expression in human breast cancer and treatment response. B Murillo-Ortiz, S Castillo-Medina, JM Malacara, L Benitez-Bribiesca. (2006) BMC Cancer 6 (1), 1-9.
  • Triggering receptor expressed on myeloid cells (TREM-1) is regulated post- transcriptionally and its ligand is present in the sera of some septic patients.
  • I Wong-Baeza, N Gonzalez-Roldan, E Ferat-Osorio, N Esquivel-Callejas, et al. (2006) Clinical & Experimental Immunology 145 (3), 448-455.
  • Expression of telomerase enzyme as predictive factor of response to first line chemotherapy with gemcitabine/carboplatin in advanced non-small cell lung cancer (IIIB and IV). M Pluma-Jimenez, S Castillo-Medina, B Murillo-Ortiz, S Labastida, et al. (2006) Journal of Clinical Oncology 24 (18_suppl), 17156-17156.
  • Outcomes associated with retinoblastoma and c-myc gene expression in patients with testicular cancer: A ten-year experience. H Astudillo-De La Vega, E Ruiz-Garcia, M Salcedo, A Torres, et al. (2006) Journal of Clinical Oncology 24 (18_suppl), 14656-14656.
  • La hemato-oncología molecular y las nuevas estrategias terapéuticas específicas en leucemia. M Martínez-Mancilla, G Zafra-de la Rosa, E Reynoso-Gómez, et al. (2006) Gaceta Medica de Mexico 142 (2), 145-150.
  • Expression of triggering receptor on myeloid cell 1 and histocompatibility complex molecules in sepsis and major abdominal surgery. N González-Roldán, E Ferat-Osorio, R Aduna-Vicente, I Wong-Baeza, et al. (2005) World Journal of Gastroenterology 11 (47), 7473.
  • A molecular analysis by gene expression profiling reveals Bik/NBK overexpression in sporadic breast tumor samples of Mexican females. N García, F Salamanca, H Astudillo-de la Vega, E Curiel-Quesada, et al. (2005) BMC Cancer 5 (1), 1-11.
  • A molecular analysis by gene expression profiling reveals BIK/NBK overexpression in sporadic breast tumors of Mexican female samples. N Garcia, H Astudillo-de la Vega, F Salamanca, I Alvarado, M Perez, et al. (2005) EJC SUPPLEMENTS 3 (2), 64-64.
  • Telomerase activity in normal human breast and cancer, association with Bcl-2, estrogen receptors (α-, β-) and clinical parameters. B Murillo, JM Malacara, M Perez, MA Pluma, C Ramirez, JA Silva, et al. (2005) Journal of Clinical Oncology 23 (16_suppl), 9675-9675.
  • Nitric oxide and prostaglandins in endothelial regulation of the contractile tone of hypertensive rats. CA Sosa-Luna, H Astudillo-de la Vega, DJ Sánchez-González, et al. (2005) Revista de Sanidad Militar 59 (1), 32-50.
  • Predicitve factors for neoadjuvant chemotherapy in locally advanced breast cancer. MA Perez, J Ruiz, H Astudillo, M Silva, J Silva, MA Pluma. (2004) Journal of Clinical Oncology 22 (14_suppl), 863-863.
  • P53, Bcl-2, PCNA expression and apoptotic rates during cervical tumorigenesis. H Astudillo, M Perez, J Silva, M Silva, S Castillo, L Benitez, P Gariglio. (2004) Journal of Clinical Oncology 22 (14_suppl), 5068-5068.
  • Pelvic exenteration for colorectal and anal canal cancer: Clinical experience of a referral cancer center. JM Ruiz Molina, E Hernandez Castillo, MA Perez Martinez, et al. (2004) ANNALS OF ONCOLOGY 15, 99-99.
  • TP53/MBM2 co-localization and differential expression analysis in laryngeal ephitelial lesions and laryngeal cancer. H Astudillo-de la Vega, N Boronat, S Castillo, J Rangel, JA Silva, M Silva, et al. (2004) ANNALS OF ONCOLOGY 15, 142-142.
  • p53, Bcl‐2, PCNA expression, and apoptotic rates during cervical tumorigenesis. H Astudillo, T Lopez, S Castillo, P Gariglio, L Benitez. (2003) Annals of the New York Academy of Sciences 1010 (1), 771-774.
  • Angiotensin II stimulates cyclooxygenase-2 mRNA expression in renal tissue from rats with kidney failure. J Hernández, H Astudillo, B Escalante. (2002) American Journal of Physiology-Renal Physiology 282 (4), F592-F598.
  • Is it possible to create human malignant cells in the laboratory? HA de la Vega, L Benítez-Bribiesca. (2000) Gaceta Medica de Mexico 136 (2), 173-174.
  • In situ polymerase chain reaction. New method for genetic diagnosis. H Astudillo-de la Vega, A Monarres-Alvarado, L Benítez-Bribiesca. (1998) Gaceta Medica de Mexico 134 (6), 749-751.
es_ES
en_US es_ES